Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Income from Continuing Operations of 90912000.0 for Q1 2026, down 218.75% year-over-year from 76560000.0 in Q1 2025, and down 852.26% quarter-over-quarter from 9547000.0 in Q4 2025.
Powered by 
Analysis
Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Income from Continuing Operations for 7 consecutive years, with 90912000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 218.75% year-over-year to 90912000.0; the TTM figure through Mar 2026 stood at 167422000.0 (down 677.04% YoY), while the FY2025 annual figure was 2070000.0, up 101.64% from the prior year.
- Income from Continuing Operations eased to 90912000.0 in Q1 2026 per IPSC's latest filing, from 9547000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 76560000.0 in Q1 2025 and bottomed at 90912000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 28507941.18 across 5 years, with a median of 31682000.0 in 2022.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 372.82% — and 2026, when it plunged 218.75%.
- Century Therapeutics' Income from Continuing Operations stood at 31682000.0 in 2022, then fell by 24.35% to 39398000.0 in 2023, then gained by 9.45% to 35673000.0 in 2024, then soared by 73.24% to 9547000.0 in 2025, then slumped by 852.26% to 90912000.0 in 2026.
- Business Quant data shows IPSC's Income from Continuing Operations at 90912000.0 in Q1 2026, 9547000.0 in Q4 2025, and 34422000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | -34.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.55 Mn |
| Mar 31, 2026 | -21.67 Mn |
| Dec 31, 2025 | -19.28 Mn |
| Sep 30, 2025 | -34.42 Mn |
| Jun 30, 2025 | -32.54 Mn |
| Mar 31, 2025 | 76.56 Mn |
| Dec 31, 2024 | -8.13 Mn |
| Sep 30, 2024 | -31.23 Mn |
| Jun 30, 2024 | -31.21 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -39.40 Mn |
| Sep 30, 2023 | -32.72 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -31.26 Mn |
| Dec 31, 2022 | -31.68 Mn |
| Sep 30, 2022 | -30.75 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -37.51 Mn |
| Dec 31, 2021 | -28.15 Mn |
| Sep 30, 2021 | -26.01 Mn |